↓ Skip to main content

Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis

Overview of attention for article published in Journal of Translational Medicine, July 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
1 X user
wikipedia
1 Wikipedia page

Citations

dimensions_citation
88 Dimensions

Readers on

mendeley
51 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis
Published in
Journal of Translational Medicine, July 2018
DOI 10.1186/s12967-018-1580-x
Pubmed ID
Authors

Qinrui Han, Ye Ma, Hao Wang, Yu Dai, Chunhui Chen, Yawei Liu, Linlin Jing, Xuegang Sun

Abstract

Necroptotic susceptibility is probably an intrinsic weakness of cancer. Here, we report that resibufogenin, a member of bufadienolide family, suppresses the growth and metastasis of colorectal cancer (CRC) through induction of necroptosis in vivo. SW480 cells with stably expressing enhanced green fluorescence protein were xenografted to BALB/c-nu mice to observe the growth of tumors. Liver metastasis was observed by injection of MC38 cells beneath the splenic capsule of mice. Protein expression was determined by immunohistochemistry, immunofluorescence and western blot. Consolidated in vitro results indicate that resibufogenin has anti-proliferative activity on CRC cells. PI staining and transmission electron microscope imaging suggest that the cell death induced by resibufogenin are mainly through necrosis, which is further confirmed by the ineffectiveness of z-VAD, a pan-caspase general inhibitor. In particular, resibufogenin induced necrosis is substantially abrogated in receptor-interacting protein kinase 3 (RIPK3) knockout mouse embryo fibroblasts. The RIP3-dependent necrosis has been classified as necroptosis. Resibufogenin triggeres necroptosis through upregulating RIP3 and phosphorylating mixed lineage kinase domain-like protein at Ser358. Resibufogenin also activates the expression of PYGL, GLUD1 and GLUL in a RIP3-dependent manner. Resibufogenin exerts cytotoxic effect by inducing reactive oxygen species accumulation which can be neutralized by N-acetylcysteine. Remarkably, resibufogenin significantly suppresses liver-metastasis from spleen implantation. The anti-neoplastic effect of this compound can be abrogated by RIP3 knockdown. Resibufogenin suppresses growth and metastasis of CRC through RIP3-mediated necroptosis.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 51 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 20%
Student > Postgraduate 5 10%
Student > Bachelor 3 6%
Student > Doctoral Student 3 6%
Student > Ph. D. Student 3 6%
Other 6 12%
Unknown 21 41%
Readers by discipline Count As %
Medicine and Dentistry 8 16%
Biochemistry, Genetics and Molecular Biology 5 10%
Immunology and Microbiology 4 8%
Agricultural and Biological Sciences 3 6%
Chemistry 3 6%
Other 3 6%
Unknown 25 49%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 August 2018.
All research outputs
#7,325,864
of 23,096,849 outputs
Outputs from Journal of Translational Medicine
#1,175
of 4,052 outputs
Outputs of similar age
#124,763
of 328,924 outputs
Outputs of similar age from Journal of Translational Medicine
#19
of 93 outputs
Altmetric has tracked 23,096,849 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 4,052 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,924 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 93 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.